The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Special issue on neurodegenerative diseases and their therapeutic approaches
Open accessAbstract
Aging is the strongest risk factor for most neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis. As the aging population is increasing, these neurodegenerative disorders are becoming major social issues in many countries. Interestingly, these diseases share a common pathological phenotype; the accumulation of misfolded and aggregated proteins in the brain. Mounting evidence suggests that there are mechanistic links between toxic protein aggregation and neurodegenerative diseases. With a better understanding of the pathogenesis of these disorders, discovery efforts for disease-modifying therapeutics have markedly increased in recent years. This special issue, titled ‘Neurodegenerative diseases and their therapeutic approaches’, discusses the underlying pathogenic mechanisms and therapeutic implications for AD and other age-associated neurodegenerative disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Degradation of the Id2 developmental regulator: targeting via N-terminal ubiquitination
Fajerman, I., Schwartz, A. L., & Ciechanover, A. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.116 · Cited by 72
Cited by
Sorted by citations
Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. D. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 267
“Revelatory endeavours for sickness-changing therapeutics have lately significantly expanded, because of a more noteworthy comprehension of the pathogenesis of these infections [22].”
BackgroundCurrent Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders
Paul, S., Bravo-Vázquez, L. A., Uribe, S. P., Reyes‐Pérez, P., & Sharma, A. K. (2020) · Cells · doi:10.3390/cells9071698 · Cited by 105
Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases
Mistretta, M., Farini, A., Torrente, Y., & Villa, C. (2023) · Brain · doi:10.1093/brain/awad014 · Cited by 45
Phytoconstituents-based nanoformulations for neurodegenerative disorders
Rajput, M. S., Nirmal, N. P., Patel, V. A., Sarkar, P. D., & Raval, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19143-5.00003-7 · Cited by 6
Marine Carbohydrate Based Therapeutics for Alzheimer Disease-Mini Review
Venkatesan, M., Karthik, R., & Ramachandran, S. (2015) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.s10010 · Cited by 5
Liu, Y., Chen, Y., Gao, M., Luo, J., Wang, Y., Wang, Y., Gao, Y., Yang, L., Wang, J., & Wang, N. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1413015 · Cited by 5
“Currently, treatments for NDs have limited effectiveness, with no existing cures available (3).”
BackgroundGodad, A. P., Vasant, T. L., Kurmi, S., & Borkar, M. R. (2026) · Springer eBooks · doi:10.1007/978-981-95-6099-8_5
Peptide-Based Molecular Glues for Targeted Protein Degradation
Aburayan, W. S., Alradwan, I. A., Alsaffar, B., Alhazzaa, O. A., Almughem, F. A., Alshehri, A. A., Alduhaymi, I. S., Fallatah, M., Alturki, M., Alshaya, H. A., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101208
Metadata
- Authors
- Kim, J., & Mook-Jung, I.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Kim, Jungsu
- Venue
- Experimental & Molecular Medicine
- Published
- 2015-03-13
- Volume
- 47
- Issue
- 3
- Pages
- e146-e146
- ISSN
- 1226-3613 (ISSN-L)
- 2092-6413
- PMC
- PMC4351416
- OpenAlex
- W2021281334
- Semantic Scholar
- 0a579c9a277a61361dc62ec9c651ada31bec8fb0
- Cited by
- 8
- References
- 1
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 1 · 2015: 1
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Experimental & Molecular Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- Seoul National University
- College of Medicine, Seoul National University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, aging, protein aggregation, protein misfolding, disease-modifying therapy, pathogenesis
- MeSH terms
- Humans, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
